Document Detail

Validation of the Dermatology Life Quality Index as an outcome measure for urticaria-related quality of life.
MedLine Citation:
PMID:  15328673     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Chronic idiopathic urticaria (CIU) is a debilitating skin disease that affects patients' quality of life (QOL). The Dermatology Life Quality Index (DLQI) assesses QOL parameters across several types of dermatologic conditions. However, an evaluation of the validity of the DLQI for use in CIU patients has not been undertaken, because CIU, unlike other chronic skin conditions, is subject to daily or weekly symptom fluctuations. OBJECTIVE: To test the reliability and validity of the DLQI in 2 samples of CIU patients treated with fexofenadine hydrochloride (20, 60, 120, or 240 mg twice daily). METHODS: Data were obtained from 2 similar multicenter, double-blind, randomized, placebo-controlled, parallel-group studies of CIU patients (n = 418 and n = 439). Patients completed the 10-item DLQI during 3 clinic visits (approximately 2 weeks apart). Clinic personnel also recorded patients' symptoms. RESULTS: The results of the DLQI items were similar to those obtained with other skin disease populations, indicating the presence of relatively symmetrical distributions. Reliability was high, demonstrating the lack of excessive random measurement error (alpha coefficient = .89 and .87 for samples 1 and 2). Factor analysis resulted in a unidimensional pattern, supporting the use of a total DLQI score. Most DLQI items distinguished patients with varying degrees of QOL impairment, highlighting the sensitivity of this instrument. Construct validity was moderate, providing evidence that the DLQI was responsive to changes in patients' clinical status. CONCLUSIONS: The DLQI is a valid, reliable, and clinically useful outcome measure for assessing QOL in CIU patients.
Richard D Lennox; Michael J Leahy
Related Documents :
19819183 - Switch from enfuvirtide to raltegravir in virologically suppressed hiv-1 infected patie...
17597413 - Patient knowledge and perspective on irritable bowel syndrome: development of a survey ...
8888243 - Thymus in myasthenia gravis: comparison of ct and pathologic findings and clinical outc...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology     Volume:  93     ISSN:  1081-1206     ISO Abbreviation:  Ann. Allergy Asthma Immunol.     Publication Date:  2004 Aug 
Date Detail:
Created Date:  2004-08-26     Completed Date:  2004-09-23     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9503580     Medline TA:  Ann Allergy Asthma Immunol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  142-6     Citation Subset:  IM    
Psychometric Technologies Inc, Hillsborough, North Carolina 27278, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Chronic Disease
Dose-Response Relationship, Drug
Double-Blind Method
Histamine H1 Antagonists / administration & dosage
Outcome Assessment (Health Care)*
Predictive Value of Tests
Pruritus / drug therapy,  psychology
Quality of Life / psychology*
Reproducibility of Results
Sensitivity and Specificity
Sickness Impact Profile
Statistics as Topic
Terfenadine / administration & dosage,  analogs & derivatives*
Treatment Outcome
Urticaria / drug therapy,  psychology*
Reg. No./Substance:
0/Histamine H1 Antagonists; 138452-21-8/fexofenadine; 50679-08-8/Terfenadine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Carboplatin desensitization.
Next Document:  Patient knowledge of immunotherapy before and after an educational intervention: a comparison of 2 m...